ARS Pharmaceuticals' neffy added to Cigna Healthcare and Navitus Health Systems formularies

From GlobeNewswire: 2025-02-20 19:02:25

ARS Pharmaceuticals announced that neffy (epinephrine nasal spray) has been added to formularies by Cigna Healthcare, Navitus Health Systems, and OptumRx, expanding access to half of all patients managing Type 1 allergic reactions. The total number of formulary platforms covering neffy is now 30. The addition of neffy to these formularies benefits around 20 million people diagnosed with severe Type I allergic reactions requiring epinephrine therapy. neffy offers a low copay price of $25 and is available without prior authorizations or restrictive step therapies for patients insured by the mentioned health plans. The FDA-approved neffy provides a needle-free alternative to injectable epinephrine, with a shelf-life of 30 months. The supplemental NDA for neffy 1 mg is expected to be available by the end of May 2025, providing more options for children with Type I allergic reactions. For more information, visit www.neffy.com/savings.



Read more at GlobeNewswire: ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and